title: [The willingness to pay for new drugs is based on ethical principles].
abstract: The County Council's board for new therapies (the NT Council) provides recommendations on the use of new drugs based on the ethical platform of priorities, founded by the Swedish parliament. The Council has formulated a policy that interprets the parliamentary ethical platform and operationalize its need and solidarity principle and cost effectiveness principle in four dimensions. The NT Council weighs the health economic evaluation of the drug and the four dimensions: the severity of the condition, the rarity of the condition, the effect size and the data reliability to determine the willingness to pay level and whether the platform allows a recommendation for using of the drug. The severity of the condition has a greater impact than the other dimensions. In the assessment of severity there is also a trade-off between prevention and treatment of manifest diseases and in prevention, the size of the risk of falling ill is of importance. A slightly higher willingness to pay level is reasonable for treatment of very rare conditions, but it is important that identified patients are not given priority over anonymous patient groups with equally strong needs.
authors: Statens Beredning för Medicinsk och Social Utvärdering - Stockholm, Sweden - SBU Stockholm , Sweden.
authors: Jan
authors: J
authors: Liliemark
authors: Läkemedelskommittèn - Landstinget Västmanland Västerås, Sweden Läkemedelskommittèn - Landstinget Västmanland Västerås, Sweden.
authors: Lars
authors: L
authors: Lööf
authors: Läkemedelsenheten - Stockholms Läns Landsting Stockholm, Sweden Läkemedelsenheten - Stockholms Läns Landsting Stockholm, Sweden.
authors: Gustaf
authors: G
authors: Befrits
authors: Regionstaben - Region Gävleborg Gävle, Sweden Regionstaben - Region Gävleborg Gävle, Sweden.
authors: Stefan
authors: S
authors: Back
authors: Prioriteringscentrum - Institutionen för medicin och hälsa Linköping, Sweden Prioriteringscentrum - Institutionen för medicin och hälsa Linköping, Sweden.
authors: Lars
authors: L
authors: Sandman
mesh_terms: D003362:Cost-Benefit Analysis / Q000379:methods*; D016527:Drug Costs / Q000941:ethics*; D006291:Health Policy; D006292:Health Priorities / Q000191:economics / Q000941:ethics; D006801:Humans; D013548:Sweden